Drugs / IL-12 & Anti-NY ESO1 TCR PBL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01457131 | Oct 2011 → Aug 2013 | kidney cancer, metastatic malignant neoplasm, metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-12 & Anti-NY ESO1 TCR PBL | “IL-12 & Anti-NY ESO1 TCR PBL” NCT01457131 ↗ |
| Action | Deplete | “The cells may then be able to seek out the cancer cells and destroy them.” NCT01457131 ↗ |
| Modality | Cell therapy | “intravenous infusion of IL-12/anti-ESO TCR gene-transduced lymphocytes” NCT01457131 ↗ |
| Route | Intravenous | “intravenous infusion of IL-12/anti-ESO TCR gene-transduced lymphocytes” NCT01457131 ↗ |